300497.SHE Jiangxi Fushine Pharmaceutical Co Ltd
- Market cap
- CNY 7.32B
- P/E
- 17.2x
- P/B
- 2.79x
- ROE
- 21.0%
- Dividend yield
- 0.75%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300497.SHE undervalued?
Graham number300497.SHE trades 46.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangxi Fushine Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Jiangxi Fushine Pharmaceutical Co Ltd yet.
Jiangxi Fushine Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections…
Full company profileJiangxi Fushine Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangxi Fushine Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 764M | 958M | 1.16B | 1.35B | 1.49B | 1.43B | 1.65B | 1.61B | 1.18B | 1.18B | 2.07B |
| Gross Profit | 326M | 363M | 429M | 581M | 601M | 433M | 214M | 138M | 53.9M | 198M | 916M |
| Operating Income | 188M | 198M | 231M | 369M | 387M | 57.0M | -134M | -229M | -287M | -61.5M | 660M |
| EBITDA | 246M | 262M | 304M | 460M | 477M | 179M | 23.0M | -31.7M | -76.3M | -61.5M | 633M |
| Net Income | 174M | 178M | 195M | 306M | 319M | 48.8M | -141M | -201M | -272M | -53.1M | 537M |
| EPS | 0.41 | 0.42 | 0.45 | 0.67 | 0.69 | 0.09 | -0.26 | -0.37 | -0.51 | -0.10 | 1.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.40B | 1.79B | 2.20B | 2.60B | 4.05B | 4.68B | 5.06B | 4.82B | 4.54B | 4.40B | 4.82B |
| Total Liabilities | 614M | 823M | 1.05B | 1.07B | 998M | 1.77B | 2.37B | 2.35B | 2.36B | 2.20B | 2.23B |
| Shareholders' Equity | 756M | 937M | 1.12B | 1.49B | 3.01B | 2.88B | 2.68B | 2.48B | 2.18B | 2.18B | 2.56B |
| Cash & Short-term Investments | 342M | 613M | 781M | 791M | 1.69B | 1.42B | 1.03B | 732M | 698M | 483M | 537M |
| Total Debt | 217M | 433M | 677M | 703M | 442M | 1.00B | 1.42B | 1.55B | 1.29B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 189M | 211M | 176M | 338M | 382M | 72.3M | -121M | -64.8M | 188M | 62.7M | - |
| Capital Expenditure | 81.3M | 99.0M | 164M | 325M | 449M | 680M | 459M | 242M | 142M | 225M | 153M |
| Free Cash Flow | 107M | 112M | 12.0M | 13.0M | -66.9M | -607M | -580M | -307M | 45.9M | -162M | 70.3M |
| Ratios | |||||||||||
| ROE | 23.0% | 19.0% | 17.4% | 20.5% | 10.6% | 1.7% | -5.3% | -8.1% | -12.5% | -2.4% | 21.0% |
| ROA | 12.4% | 9.9% | 8.9% | 11.8% | 7.9% | 1.0% | -2.8% | -4.2% | -6.0% | -1.2% | 11.2% |
| Net Profit Margin | 22.8% | 18.5% | 16.7% | 22.6% | 21.4% | 3.4% | -8.6% | -12.5% | -23.1% | -4.5% | 26.0% |
| Debt to Equity | 0.29x | 0.46x | 0.61x | 0.47x | 0.15x | 0.35x | 0.53x | 0.62x | 0.59x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangxi Fushine Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.75%
- Forward dividend
- 0.05 CNY
- Payout ratio
- -
- Ex-dividend date
- Aug 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 54.8M | 0.10 | - |
| 2024 | CNY 55.5M | 0.10 | - |
| 2023 | CNY 55.8M | 0.10 | - |
| 2022 | CNY 54.6M | 0.10 | - |
| 2021 | CNY 110M | 0.20 | 225.3% |
| 2020 | CNY 56.8M | 0.12 | 17.8% |
| 2019 | CNY 43.9M | 0.10 | 14.4% |
| 2018 | CNY 79.7M | 0.18 | 41.0% |
| 2017 | CNY 70.8M | 0.17 | 39.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.6:1 on May 18, 2020.
Who owns Jiangxi Fushine Pharmaceutical Co Ltd
- Insiders 27.37%
- Institutions 0.51%
- Public & others 72.12%
- Shares outstanding 539M
- Free float 413M
Jiangxi Fushine Pharmaceutical Co Ltd company profile
- Company name
- Jiangxi Fushine Pharmaceutical Co Ltd
- Ticker
- 300497.SHE
- ISIN
- CNE1000024Z7
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,663
- Fiscal year end
- December
- Address
- No. 2, Yuli Industrial Zone, Jingdezhen, China, 333000
- Phone
- 86 79 8269 9929
- Website
- fushine.cn
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancroid. The company also provides tazobactam, piperacillin, sultamicillin, sultamicillin tosylate, tazobactam sodium, sulbactam sodium, sulbactam pivoxil, avibactam sodium, sitafloxacin, torasemide, moxifloxacin hydrochloride, paroxetine hydrochloride, and berberine hydrochloride products. In addition, it offers lithium-ion battery electrolyte additives; and microbial protein, amino acid water-soluble fertilizer, and other bio-fermentation products. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. Jiangxi Fushine Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Jingdezhen, China.
Jiangxi Fushine Pharmaceutical Co Ltd management
8- Mr. Jian Hua BaoPresident & Chairman · born 1977
- Mr. Jizu ChengCEO & Director · born 1960
- Mr. Guang YangFinancial Director · born 1987
- Ms. Yun PengDeputy GM & Secretary of the Board · born 1992
- Mr. Xiang Ming ZhangDeputy General Manager · born 1975
- Ms. Ying LiuDeputy General Manager · born 1981
- Mr. Haipeng WeiDeputy General Manager · born 1976
- Haiyan XieAccounting Supervisor